메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

Guide Outdoor、SHOT Show 2026でApexVisionを披露：ラスベガスで幕を開ける超高精細時代

[ 메디채널 황정호 기자 ] ラスベガス、2026年1月20日 -- CES 2026で高い評価を受けたデビューから間もないGuide Outdoorは、2026年1月20日～23日にラスベガスで開催されるSHOT Show 2026のブース番号40516にて、ApexVisionを披露します。射撃、狩猟、アウトドア業界を代表する主要イベントであるSHOT Showは、業界のプロフェッショナルが一堂に会し、今後1年を形作る技術動向を探る場です。ApexVisionは、超高精細サーマルイメージングにおける大きな前進を示すものであり、狩猟向けに最適化された光学機器は、会期を通じて本格的なハンターやアウトドア愛好家から高い関心を集めることが期待されています。 ApexVisionは、ハードウェアとソフトウェアの深い統合により、サーマルイメージング性能における重要な進歩を示しています。先進的なApexCore S1赤外線検出器、高性能なNexus 1.0処理プラットフォーム、AI駆動のHyper-light 2.0アルゴリズムを組み合わせることで、これらの技術が相互に連携し、卓越した画像ディテール、優れたコントラストとエッジ強調、雑音抑圧、さらには高倍率時や高速で動くターゲットにおいても遅延のない映像表示を実現します。 SHOT Show
- 황정호 기자
- 2026-01-20 17:48
Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing in humans. - ASC37's average in vitro activity was approximately 5-, 4-, and 4-fold more potent than retatrutide for GLP-1R, GIPR and GCGR, respectively. - Submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC37 injection is expected in the second quarter of 2026. HONG KONG, Jan. 20, 2026 -- Ascletis Pharma Inc. (HK
- 김갑성 기자
- 2026-01-20 17:00
가이드 아웃도어, 샷쇼 2026에서 ApexVision 공개…라스베이거스에서 초고해상도 시대 개막

[ 메디채널 황정호 기자 ] 라스베이거스 2026년 1월 20일 -- 최근 개최된 세계 최대 IT•가전 전시회 CES 2026에서 호평 속에 데뷔한 가이드 아웃도어(Guide outdoor)가 1월 20일부터 23일까지 나흘간 미국 라스베이거스에서 열리는 샷쇼 2026(SHOT Show 2026, 부스 #40516)에서 ApexVision을 선보일 예정이다. 샷쇼는 사격•사냥•아웃도어 산업을 대표하는 글로벌 전시회로, 업계 전문가들이 모여 향후 한 해를 이끌 주요 기술을 탐구하는 자리다. 초고해상도 열화상 기술의 도약을 보여줄 맞춤형 사냥용 광학 장비 ApexVision은 행사 기간 동안 전문 사냥꾼과 아웃도어 애호가들로부터 큰 관심을 받을 것으로 기대된다. ApexVision은 하드웨어와 소프트웨어를 긴밀히 통합하여 열화상 성능을 획기적으로 발전시켰다. 첨단 ApexCore S1 적외선 검출기와 고성능 Nexus 1.0 처리 플랫폼, 인공지능(AI) 기반 Hyper-light 2.0 알고리즘을 결합해 뛰어난 이미지 디테일과 우수한 대비 및 에지 향상, 효과적인 노이즈 억제와 지연 없는 부드러운 시각화 성능을 구현한다. 이로써
- 황정호 기자
- 2026-01-20 17:00
SmallRig Signals Strategic Shift at CES Debut, Reframing Imaging Innovation Around Everyday Creation

LAS VEGAS, Jan. 20, 2026 -- SmallRig, a global specialized provider of imaging solutions, made its first appearance at CES 2026 from January 6 to 9, marking a milestone moment in its global strategy. Reimagining the CES Booth as a Co-Creation Hub Alongside the international debut of the S70 wireless microphone and the showcase of several recently released products, SmallRig presented a booth concept that stood apart from conventional exhibition formats. Rather than focusing solely on product displays, the brand transformed its space into a "creator service station," of
- 김장윤(JASON KIM) 기자
- 2026-01-20 16:19
Merck and ChemLex Sign Memorandum of Understanding to Advance Automated Chemistry and Technological Innovation

[ 메디채널 김갑성 기자 ] Strategic collaboration establishes a framework to integrate automated experimentation and advanced chemistry workflows to accelerate research and discovery in Life Science and Electronics SINGAPORE and SHANGHAI, Jan. 20, 2026 -- Merck, a leading science and technology company, and ChemLex, a Singapore-headquartered innovation company pioneering AI-driven automated chemical synthesis, today announced the signing of a Memorandum of Understanding (MOU) to explore a strategic collaboration in evolving R&D paradigms. The MOU reflects a shared commitment to adv
- 김갑성 기자
- 2026-01-20 16:17
Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology

DAEJEON, South Korea, Jan. 20, 2026 -- Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK. Under the terms of the agreement, Tesaro will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme™ technology, for the development and commercialization of a subcutaneous formulation of dostarlimab, a programmed death receptor-1 (PD-1) blocking antibody. Alteogen will receive an upfront payment of US$20 million and is eligible to receive milestone payments up
- 김갑성 기자
- 2026-01-20 15:55
Infinitus Recognised as a Top Employer in China for 2026 for the Sixth Consecutive Year

GUANGZHOU, China, Jan. 20, 2026 -- Infinitus, a leader in the health and wellness industry, is pleased to announce that it has been recognised as a "Top Employer in China for 2026" by the Top Employers Institute, marking the sixth consecutive year the company has earned this distinguished honour. The Certification follows the Institute's rigorous annual HR Best Practices Survey and independent validation process and was announced on January 15, 2026. At Infinitus, people are at the heart of the organisation's long-term development — the foundation of its business and
- 김갑성 기자
- 2026-01-20 15:51
LSBF Singapore Campus and Deloitte Elevate Diploma Education in Singapore with Industry-Driven Learning

SINGAPORE, Jan. 20, 2026 -- Building on a successful collaboration launched in 2024, London School of Business and Finance (LSBF) Singapore Campus and Deloitte are taking their partnership to the next level, bringing real-world industry expertise directly into LSBF's Diploma, Higher Diploma, and Career Immersion programmes. This expanded collaboration underscores a shared mission: to produce career-ready graduates equipped with both academic rigour and practical insights from one of the world's leading professional services firms. Dual-Branded, Industry-Endorsed Programmes
- 황정호 기자
- 2026-01-20 15:43
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers

SINGAPORE, Jan. 20, 2026 -- Klook, a leading pan-regional experiences platform in Asia Pacific, finds from traveler reviews that people choose different destinations to fulfil different jobs-to-be-done. When time is limited, better-known cities serve the role of enabling travelers to step out of their everyday routines efficiently, offering familiarity, convenience, and pace control. Lesser-known cities fulfil a different job. They let travelers connect with a destination, inviting travelers to experience the place in a more immersive and unstructured way. All Klo
- 김장윤(JASON KIM) 기자
- 2026-01-20 15:40
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch

MELBOURNE, Australia and INDIANAPOLIS, Ind., Jan. 20, 2026 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025). Q4 2025 Highlights Full-year (FY) 2025 unaudited Group revenue of approximately US$804 million (A$1.2 billion[1]), in line with upgraded guidance of US$800-$820 million[2] (previously US$770-800 million). Q4 2025 unaudited Group revenue of approximately US$208 million, up 46% year-over-year. Precision Me
- 김갑성 기자
- 2026-01-20 15:16

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-01-21_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 21일 08시 40분